INC Research (NASDAQ:SYNH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The brokerage presently has a $41.00 price target on the stock. Zacks Investment Research‘s target price suggests a potential upside of 10.81% from the company’s current price.
According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
Other analysts have also recently issued research reports about the stock. Jefferies Group reiterated a “buy” rating and issued a $55.00 price target on shares of INC Research in a report on Friday, November 10th. Credit Suisse Group cut their price target on shares of INC Research from $68.00 to $54.00 and set an “outperform” rating on the stock in a report on Tuesday, November 14th. KeyCorp reiterated a “market perform” rating and issued a $46.00 price target (down previously from $68.00) on shares of INC Research in a report on Monday, November 13th. TheStreet cut shares of INC Research from a “b-” rating to a “c” rating in a report on Monday, December 18th. Finally, BidaskClub upgraded shares of INC Research from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $48.89.
In other news, CAO Christopher L. Gaenzle sold 1,470 shares of the business’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $41.00, for a total transaction of $60,270.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.24% of the company’s stock.
WARNING: “INC Research (SYNH) Raised to Buy at Zacks Investment Research” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/13/inc-research-synh-raised-to-buy-at-zacks-investment-research.html.
INC Research Company Profile
Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with MarketBeat.com's FREE daily email newsletter.